- Home
- LCNB vs DMAC Comparison
LCNB vs DMAC Comparison
Compare LCNB & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCNB
- DMAC
- Stock Information
- Founded
- LCNB 1877
- DMAC 2000
- Country
- LCNB United States
- DMAC United States
- Employees
- LCNB N/A
- DMAC N/A
- Industry
- LCNB Major Banks
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- LCNB Finance
- DMAC Health Care
- Exchange
- LCNB Nasdaq
- DMAC Nasdaq
- Market Cap
- LCNB 206.8M
- DMAC 178.0M
- IPO Year
- LCNB N/A
- DMAC N/A
- Fundamental
- Price
- LCNB $14.12
- DMAC $3.63
- Analyst Decision
- LCNB
- DMAC Strong Buy
- Analyst Count
- LCNB 0
- DMAC 2
- Target Price
- LCNB N/A
- DMAC $8.00
- AVG Volume (30 Days)
- LCNB 14.4K
- DMAC 110.0K
- Earning Date
- LCNB 07-22-2025
- DMAC 08-06-2025
- Dividend Yield
- LCNB 6.17%
- DMAC N/A
- EPS Growth
- LCNB 31.98
- DMAC N/A
- EPS
- LCNB 1.14
- DMAC N/A
- Revenue
- LCNB $82,862,000.00
- DMAC N/A
- Revenue This Year
- LCNB N/A
- DMAC N/A
- Revenue Next Year
- LCNB $6.72
- DMAC N/A
- P/E Ratio
- LCNB $12.47
- DMAC N/A
- Revenue Growth
- LCNB 18.71
- DMAC N/A
- 52 Week Low
- LCNB $12.42
- DMAC $2.14
- 52 Week High
- LCNB $17.92
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- LCNB 44.72
- DMAC 46.56
- Support Level
- LCNB $13.75
- DMAC $4.02
- Resistance Level
- LCNB $15.06
- DMAC $4.17
- Average True Range (ATR)
- LCNB 0.41
- DMAC 0.25
- MACD
- LCNB -0.03
- DMAC -0.04
- Stochastic Oscillator
- LCNB 28.24
- DMAC 37.89
About LCNB LCNB Corporation
LCNB Corp operates within the financial sector in the United States. As the holding company of the National Bank, it conducts the business of providing commercial and personal banking services. Its suite of banking products includes commercial and industrial loans, consumer loans, safe deposit boxes, night depositories, cashier's checks, utility bill collections and notary public service. Besides, it provides the avenue of United States Treasury notes, the United States agency notes, certificates of deposit, and equity securities.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.